Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer ; volume:36 ; number:1 ; day:26 ; month:12 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of the Egyptian National Cancer Institute / Egyptian National Cancer Institute; 36, Heft 1 (26.12.2024), 1-9, 12.2024
- Creator
-
Naguib, Engy Mohammed
Ismail, EF
Badran, DI
Sherief, MH
El-Abaseri, TB
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43046-024-00250-2
- URN
-
urn:nbn:de:101:1-2503010626356.011764473858
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Naguib, Engy Mohammed
- Ismail, EF
- Badran, DI
- Sherief, MH
- El-Abaseri, TB
- SpringerLink (Online service)
Other Objects (12)
Double trouble: how c-MET and HER2 fuel bladder cancer progression
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
c-Met inhibitors
Klinische Relevanz der Expression von c-Met, HGF, SF und HER2 beim nodal-positiven Mammakarzinom
Die c-MET- und HER2-Expressionen beim Magenkarzinom und deren Korrelation mit klinisch-pathologischen Parametern
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
P3H4 is correlated with clinicopathological features and prognosis in bladder cancer
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
Double trouble: how c-MET and HER2 fuel bladder cancer progression
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
c-Met inhibitors
Klinische Relevanz der Expression von c-Met, HGF, SF und HER2 beim nodal-positiven Mammakarzinom
Die c-MET- und HER2-Expressionen beim Magenkarzinom und deren Korrelation mit klinisch-pathologischen Parametern
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
P3H4 is correlated with clinicopathological features and prognosis in bladder cancer
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
Double trouble: how c-MET and HER2 fuel bladder cancer progression
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
c-Met inhibitors
Klinische Relevanz der Expression von c-Met, HGF, SF und HER2 beim nodal-positiven Mammakarzinom
Die c-MET- und HER2-Expressionen beim Magenkarzinom und deren Korrelation mit klinisch-pathologischen Parametern
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
P3H4 is correlated with clinicopathological features and prognosis in bladder cancer